We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Innovative Smartphone and AI-Based Tests Featured at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022

Scientists have developed a cheap, convenient smartphone test for monitoring patients at risk for dangerous blood clots. More...

Research demonstrating that this test works, along with a second study on using artificial intelligence (AI) to improve testing and treatment for people with kidney stones, will be presented at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo. Both studies could help resolve longstanding challenges in healthcare and laboratory testing.

Test with Smartphone App May Predict Blood Clot Risk

People who take the blood-thinning medication warfarin to prevent blood clots - which can lead to heart attacks - need frequent blood testing to ensure that the drug is working. Currently, this testing occurs in a clinical laboratory or with expensive at-home testing systems. It involves a particular measure of the time it takes for a clot to form, called prothrombin time (PT), and calculating the international normalized ratio (INR) so doctors can compare results between different tests or laboratories.

A team of researchers from the University of Washington (Seattle, WA, USA) developed a test that quickly and inexpensively determines PT/INR using a smartphone. The test uses a smartphone's built-in vibration motor and camera to track movement of a copper particle in a drop of blood. To see whether the test works, the researchers tested blood from 140 anonymous patients. The team also tested blood from 79 patients with known blood-clotting issues. In both groups, the new test produced results similar to laboratory PT/INR tests. As a next step, the researchers are planning to research whether patients can use the new test by themselves at home. The envision it being helpful for people in rural areas, to minimize long and increasingly expensive trips to doctors. The team hopes the test will lead to more people spending more time in the desirable PT/INR range, which would mean they are not at risk for clots or (on the flipside) for uncontrolled bleeding.

"The goal is to decrease complications while making PT/INR testing more convenient and less expensive," said Kelly Michaelsen, MD, PhD, who led the team.

Improving Kidney Stone Analysis and Treatment

Kidney stones are common, affecting more than 1 in 10 people. If left untreated, these hard deposits made of minerals and salts can lead to severe pain, urinary tract infections, and loss of kidney function. Effective treatment and prevention rely on knowing what stones are made of, which is often determined through a manual process using Fourier transform infrared spectroscopy (FTIR). However, mistakes in FTIR interpretation and reporting can lead to inappropriate treatments and undermine efforts to prevent future kidney stones through medication, diet, and lifestyle changes.

To improve diagnosis and better guide treatment, researchers at Mayo Clinic (Rochester, MN, USA) created a group of AI-trained algorithms that analyze FTIR kidney stone composition results. The researchers then conducted a study to determine whether the algorithms could find errors in kidney stone composition results that had been reviewed and reported by a clinical laboratory technologist. Within the 12-month study period, these AI-trained algorithms reviewed manual analyses of 81,517 kidney stones. While the technologist's and AI's interpretations agreed 90% of the time, the researchers determined that manual entry errors and/or incorrect technologist interpretations before use of AI occurred at a rate nearly eight times higher than after the start of AI use.

"Clinical laboratories continuously adopt technology to improve the accuracy of lab tests. By adopting AI, clinical laboratories can reduce errors in results sent to physicians. This study is an example of how the fields of laboratory medicine, data science, information technology, and biostatistics can work together to improve patient care," said Patrick Day, MPH, MLS (ASCP), who led the team.

Related Links:
University of Washington 
Mayo Clinic 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Hematology Consumables
Bioblood Devices
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.